TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Non-Insulin Therapies for Diabetes Market Insights and Forecast to 2028

Global Non-Insulin Therapies for Diabetes Market Insights and Forecast to 2028

  • Category:Life Sciences
  • Published on : 23 July 2022
  • Pages :126
  • Formats:
  • Report Code:SMR-7229061
OfferClick for best price

Best Price: $3920

NonInsulin Therapies for Diabetes Market Size, Share 2022


Market Analysis and Insights: Global NonInsulin Therapies for Diabetes Market

The global NonInsulin Therapies for Diabetes market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global NonInsulin Therapies for Diabetes market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global NonInsulin Therapies for Diabetes market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global NonInsulin Therapies for Diabetes market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global NonInsulin Therapies for Diabetes market.

Global NonInsulin Therapies for Diabetes Scope and Market Size

Non-Insulin Therapies for Diabetes market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Non-Insulin Therapies for Diabetes market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

Alpha-glucosidase Inhibitors

Amylin Agonists

Biguanides

Dipeptidyl Peptidase-4 (DPP4) Inhibitors

Glinides / Meglitinides

GLP-1 Analogs / GLP-1 Agonists

Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors

Sulfonylureas

Thiazolidinediones

Others

Segment by Application

Monitoring

Diagnosis

Treatment

Others

By Company

GSK

Eli Lilly

Sumitomo Dainippon Pharma

Intarcia Therapeutics

Servier

Pfizer

Merck

Dong-A Pharmaceutical

Luye Pharma Group

Eurofarma

Geropharm

Alkem Labs

SatRx

Jiangsu Hansoh Pharmaceutical

Novo Nordisk

Emisphere

Uni-Bio Science Group

Takeda

3SBio

Jiangsu Hengrui Medicine

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes NonInsulin Therapies for Diabetes product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of NonInsulin Therapies for Diabetes, with price, sales, revenue, and global market share of NonInsulin Therapies for Diabetes from 2019 to 2022.

Chapter 3, the NonInsulin Therapies for Diabetes competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the NonInsulin Therapies for Diabetes breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the NonInsulin Therapies for Diabetes market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of NonInsulin Therapies for Diabetes.

Chapter 13, 14, and 15, to describe NonInsulin Therapies for Diabetes sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 NonInsulin Therapies for Diabetes Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global Non-Insulin Therapies for Diabetes Market Insights and Forecast to 2028
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 126 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Alpha-glucosidase Inhibitors
1.2.3 Amylin Agonists
1.2.4 Biguanides
1.2.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
1.2.6 Glinides / Meglitinides
1.2.7 GLP-1 Analogs / GLP-1 Agonists
1.2.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
1.2.9 Sulfonylureas
1.2.10 Thiazolidinediones
1.2.11 Others
1.3 Market by Application
1.3.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Monitoring
1.3.3 Diagnosis
1.3.4 Treatment
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-Insulin Therapies for Diabetes Market Perspective (2017-2028)
2.2 Non-Insulin Therapies for Diabetes Growth Trends by Region
2.2.1 Non-Insulin Therapies for Diabetes Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Non-Insulin Therapies for Diabetes Historic Market Size by Region (2017-2022)
2.2.3 Non-Insulin Therapies for Diabetes Forecasted Market Size by Region (2023-2028)
2.3 Non-Insulin Therapies for Diabetes Market Dynamics
2.3.1 Non-Insulin Therapies for Diabetes Industry Trends
2.3.2 Non-Insulin Therapies for Diabetes Market Drivers
2.3.3 Non-Insulin Therapies for Diabetes Market Challenges
2.3.4 Non-Insulin Therapies for Diabetes Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue
3.1.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue (2017-2022)
3.1.2 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Players (2017-2022)
3.2 Global Non-Insulin Therapies for Diabetes Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Insulin Therapies for Diabetes Revenue
3.4 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio
3.4.1 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Insulin Therapies for Diabetes Revenue in 2021
3.5 Non-Insulin Therapies for Diabetes Key Players Head office and Area Served
3.6 Key Players Non-Insulin Therapies for Diabetes Product Solution and Service
3.7 Date of Enter into Non-Insulin Therapies for Diabetes Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Insulin Therapies for Diabetes Breakdown Data by Type
4.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Type (2017-2022)
4.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2023-2028)
5 Non-Insulin Therapies for Diabetes Breakdown Data by Application
5.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Application (2017-2022)
5.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Non-Insulin Therapies for Diabetes Market Size (2017-2028)
6.2 North America Non-Insulin Therapies for Diabetes Market Size by Type
6.2.1 North America Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022)
6.2.2 North America Non-Insulin Therapies for Diabetes Market Size by Type (2023-2028)
6.2.3 North America Non-Insulin Therapies for Diabetes Market Share by Type (2017-2028)
6.3 North America Non-Insulin Therapies for Diabetes Market Size by Application
6.3.1 North America Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022)
6.3.2 North America Non-Insulin Therapies for Diabetes Market Size by Application (2023-2028)
6.3.3 North America Non-Insulin Therapies for Diabetes Market Share by Application (2017-2028)
6.4 North America Non-Insulin Therapies for Diabetes Market Size by Country
6.4.1 North America Non-Insulin Therapies for Diabetes Market Size by Country (2017-2022)
6.4.2 North America Non-Insulin Therapies for Diabetes Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Non-Insulin Therapies for Diabetes Market Size (2017-2028)
7.2 Europe Non-Insulin Therapies for Diabetes Market Size by Type
7.2.1 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022)
7.2.2 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2023-2028)
7.2.3 Europe Non-Insulin Therapies for Diabetes Market Share by Type (2017-2028)
7.3 Europe Non-Insulin Therapies for Diabetes Market Size by Application
7.3.1 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022)
7.3.2 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2023-2028)
7.3.3 Europe Non-Insulin Therapies for Diabetes Market Share by Application (2017-2028)
7.4 Europe Non-Insulin Therapies for Diabetes Market Size by Country
7.4.1 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2017-2022)
7.4.2 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size (2017-2028)
8.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type
8.2.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Type (2017-2028)
8.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application
8.3.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Application (2017-2028)
8.4 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region
8.4.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Non-Insulin Therapies for Diabetes Market Size (2017-2028)
9.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Type
9.2.1 Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022)
9.2.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2023-2028)
9.2.3 Latin America Non-Insulin Therapies for Diabetes Market Share by Type (2017-2028)
9.3 Latin America Non-Insulin Therapies for Diabetes Market Size by Application
9.3.1 Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022)
9.3.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2023-2028)
9.3.3 Latin America Non-Insulin Therapies for Diabetes Market Share by Application (2017-2028)
9.4 Latin America Non-Insulin Therapies for Diabetes Market Size by Country
9.4.1 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2017-2022)
9.4.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size (2017-2028)
10.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type
10.2.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Type (2017-2028)
10.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application
10.3.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Application (2017-2028)
10.4 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country
10.4.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Non-Insulin Therapies for Diabetes Introduction
11.1.4 GSK Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.1.5 GSK Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Introduction
11.2.4 Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.2.5 Eli Lilly Recent Developments
11.3 Sumitomo Dainippon Pharma
11.3.1 Sumitomo Dainippon Pharma Company Details
11.3.2 Sumitomo Dainippon Pharma Business Overview
11.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Introduction
11.3.4 Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.3.5 Sumitomo Dainippon Pharma Recent Developments
11.4 Intarcia Therapeutics
11.4.1 Intarcia Therapeutics Company Details
11.4.2 Intarcia Therapeutics Business Overview
11.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Introduction
11.4.4 Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.4.5 Intarcia Therapeutics Recent Developments
11.5 Servier
11.5.1 Servier Company Details
11.5.2 Servier Business Overview
11.5.3 Servier Non-Insulin Therapies for Diabetes Introduction
11.5.4 Servier Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.5.5 Servier Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Non-Insulin Therapies for Diabetes Introduction
11.6.4 Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.6.5 Pfizer Recent Developments
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Non-Insulin Therapies for Diabetes Introduction
11.7.4 Merck Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.7.5 Merck Recent Developments
11.8 Dong-A Pharmaceutical
11.8.1 Dong-A Pharmaceutical Company Details
11.8.2 Dong-A Pharmaceutical Business Overview
11.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
11.8.4 Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.8.5 Dong-A Pharmaceutical Recent Developments
11.9 Luye Pharma Group
11.9.1 Luye Pharma Group Company Details
11.9.2 Luye Pharma Group Business Overview
11.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Introduction
11.9.4 Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.9.5 Luye Pharma Group Recent Developments
11.10 Eurofarma
11.10.1 Eurofarma Company Details
11.10.2 Eurofarma Business Overview
11.10.3 Eurofarma Non-Insulin Therapies for Diabetes Introduction
11.10.4 Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.10.5 Eurofarma Recent Developments
11.11 Geropharm
11.11.1 Geropharm Company Details
11.11.2 Geropharm Business Overview
11.11.3 Geropharm Non-Insulin Therapies for Diabetes Introduction
11.11.4 Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.11.5 Geropharm Recent Developments
11.12 Alkem Labs
11.12.1 Alkem Labs Company Details
11.12.2 Alkem Labs Business Overview
11.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Introduction
11.12.4 Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.12.5 Alkem Labs Recent Developments
11.13 SatRx
11.13.1 SatRx Company Details
11.13.2 SatRx Business Overview
11.13.3 SatRx Non-Insulin Therapies for Diabetes Introduction
11.13.4 SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.13.5 SatRx Recent Developments
11.14 Jiangsu Hansoh Pharmaceutical
11.14.1 Jiangsu Hansoh Pharmaceutical Company Details
11.14.2 Jiangsu Hansoh Pharmaceutical Business Overview
11.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
11.14.4 Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.14.5 Jiangsu Hansoh Pharmaceutical Recent Developments
11.15 Novo Nordisk
11.15.1 Novo Nordisk Company Details
11.15.2 Novo Nordisk Business Overview
11.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Introduction
11.15.4 Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.15.5 Novo Nordisk Recent Developments
11.16 Emisphere
11.16.1 Emisphere Company Details
11.16.2 Emisphere Business Overview
11.16.3 Emisphere Non-Insulin Therapies for Diabetes Introduction
11.16.4 Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.16.5 Emisphere Recent Developments
11.17 Uni-Bio Science Group
11.17.1 Uni-Bio Science Group Company Details
11.17.2 Uni-Bio Science Group Business Overview
11.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Introduction
11.17.4 Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.17.5 Uni-Bio Science Group Recent Developments
11.18 Takeda
11.18.1 Takeda Company Details
11.18.2 Takeda Business Overview
11.18.3 Takeda Non-Insulin Therapies for Diabetes Introduction
11.18.4 Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.18.5 Takeda Recent Developments
11.19 3SBio
11.19.1 3SBio Company Details
11.19.2 3SBio Business Overview
11.19.3 3SBio Non-Insulin Therapies for Diabetes Introduction
11.19.4 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.19.5 3SBio Recent Developments
11.20 Jiangsu Hengrui Medicine
11.20.1 Jiangsu Hengrui Medicine Company Details
11.20.2 Jiangsu Hengrui Medicine Business Overview
11.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Introduction
11.20.4 Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022)
11.20.5 Jiangsu Hengrui Medicine Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Alpha-glucosidase Inhibitors
Table 3. Key Players of Amylin Agonists
Table 4. Key Players of Biguanides
Table 5. Key Players of Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Table 6. Key Players of Glinides / Meglitinides
Table 7. Key Players of GLP-1 Analogs / GLP-1 Agonists
Table 8. Key Players of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Table 9. Key Players of Sulfonylureas
Table 10. Key Players of Thiazolidinediones
Table 11. Key Players of Others
Table 12. Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 13. Global Non-Insulin Therapies for Diabetes Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 14. Global Non-Insulin Therapies for Diabetes Market Size by Region (2017-2022) & (US$ Million)
Table 15. Global Non-Insulin Therapies for Diabetes Market Share by Region (2017-2022)
Table 16. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 17. Global Non-Insulin Therapies for Diabetes Market Share by Region (2023-2028)
Table 18. Non-Insulin Therapies for Diabetes Market Trends
Table 19. Non-Insulin Therapies for Diabetes Market Drivers
Table 20. Non-Insulin Therapies for Diabetes Market Challenges
Table 21. Non-Insulin Therapies for Diabetes Market Restraints
Table 22. Global Non-Insulin Therapies for Diabetes Revenue by Players (2017-2022) & (US$ Million)
Table 23. Global Non-Insulin Therapies for Diabetes Revenue Share by Players (2017-2022)
Table 24. Global Top Non-Insulin Therapies for Diabetes by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2021)
Table 25. Ranking of Global Top Non-Insulin Therapies for Diabetes Companies by Revenue (US$ Million) in 2021
Table 26. Global 5 Largest Players Market Share by Non-Insulin Therapies for Diabetes Revenue (CR5 and HHI) & (2017-2022)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Non-Insulin Therapies for Diabetes Product Solution and Service
Table 29. Date of Enter into Non-Insulin Therapies for Diabetes Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022) & (US$ Million)
Table 32. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2017-2022)
Table 33. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 34. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2023-2028)
Table 35. Global Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022) & (US$ Million)
Table 36. Global Non-Insulin Therapies for Diabetes Revenue Share by Application (2017-2022)
Table 37. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 38. Global Non-Insulin Therapies for Diabetes Revenue Share by Application (2023-2028)
Table 39. North America Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022) & (US$ Million)
Table 40. North America Non-Insulin Therapies for Diabetes Market Size by Type (2023-2028) & (US$ Million)
Table 41. North America Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022) & (US$ Million)
Table 42. North America Non-Insulin Therapies for Diabetes Market Size by Application (2023-2028) & (US$ Million)
Table 43. North America Non-Insulin Therapies for Diabetes Market Size by Country (2017-2022) & (US$ Million)
Table 44. North America Non-Insulin Therapies for Diabetes Market Size by Country (2023-2028) & (US$ Million)
Table 45. Europe Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022) & (US$ Million)
Table 46. Europe Non-Insulin Therapies for Diabetes Market Size by Type (2023-2028) & (US$ Million)
Table 47. Europe Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022) & (US$ Million)
Table 48. Europe Non-Insulin Therapies for Diabetes Market Size by Application (2023-2028) & (US$ Million)
Table 49. Europe Non-Insulin Therapies for Diabetes Market Size by Country (2017-2022) & (US$ Million)
Table 50. Europe Non-Insulin Therapies for Diabetes Market Size by Country (2023-2028) & (US$ Million)
Table 51. Asia Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022) & (US$ Million)
Table 52. Asia Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2023-2028) & (US$ Million)
Table 53. Asia Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022) & (US$ Million)
Table 54. Asia Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2023-2028) & (US$ Million)
Table 55. Asia Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2017-2022) & (US$ Million)
Table 56. Asia Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2023-2028) & (US$ Million)
Table 57. Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022) & (US$ Million)
Table 58. Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2023-2028) & (US$ Million)
Table 59. Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022) & (US$ Million)
Table 60. Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2023-2028) & (US$ Million)
Table 61. Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2017-2022) & (US$ Million)
Table 62. Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2023-2028) & (US$ Million)
Table 63. Middle East and Africa Non-Insulin Therapies for Diabetes Market Size by Type (2017-2022) & (US$ Million)
Table 64. Middle East and Africa Non-Insulin Therapies for Diabetes Market Size by Type (2023-2028) & (US$ Million)
Table 65. Middle East and Africa Non-Insulin Therapies for Diabetes Market Size by Application (2017-2022) & (US$ Million)
Table 66. Middle East and Africa Non-Insulin Therapies for Diabetes Market Size by Application (2023-2028) & (US$ Million)
Table 67. Middle East and Africa Non-Insulin Therapies for Diabetes Market Size by Country (2017-2022) & (US$ Million)
Table 68. Middle East and Africa Non-Insulin Therapies for Diabetes Market Size by Country (2023-2028) & (US$ Million)
Table 69. GSK Company Details
Table 70. GSK Business Overview
Table 71. GSK Non-Insulin Therapies for Diabetes Product
Table 72. GSK Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 73. GSK Recent Developments
Table 74. Eli Lilly Company Details
Table 75. Eli Lilly Business Overview
Table 76. Eli Lilly Non-Insulin Therapies for Diabetes Product
Table 77. Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 78. Eli Lilly Recent Developments
Table 79. Sumitomo Dainippon Pharma Company Details
Table 80. Sumitomo Dainippon Pharma Business Overview
Table 81. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product
Table 82. Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 83. Sumitomo Dainippon Pharma Recent Developments
Table 84. Intarcia Therapeutics Company Details
Table 85. Intarcia Therapeutics Business Overview
Table 86. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product
Table 87. Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 88. Intarcia Therapeutics Recent Developments
Table 89. Servier Company Details
Table 90. Servier Business Overview
Table 91. Servier Non-Insulin Therapies for Diabetes Product
Table 92. Servier Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 93. Servier Recent Developments
Table 94. Pfizer Company Details
Table 95. Pfizer Business Overview
Table 96. Pfizer Non-Insulin Therapies for Diabetes Product
Table 97. Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 98. Pfizer Recent Developments
Table 99. Merck Company Details
Table 100. Merck Business Overview
Table 101. Merck Non-Insulin Therapies for Diabetes Product
Table 102. Merck Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 103. Merck Recent Developments
Table 104. Dong-A Pharmaceutical Company Details
Table 105. Dong-A Pharmaceutical Business Overview
Table 106. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product
Table 107. Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 108. Dong-A Pharmaceutical Recent Developments
Table 109. Luye Pharma Group Company Details
Table 110. Luye Pharma Group Business Overview
Table 111. Luye Pharma Group Non-Insulin Therapies for Diabetes Product
Table 112. Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 113. Luye Pharma Group Recent Developments
Table 114. Eurofarma Company Details
Table 115. Eurofarma Business Overview
Table 116. Eurofarma Non-Insulin Therapies for Diabetes Product
Table 117. Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 118. Eurofarma Recent Developments
Table 119. Geropharm Company Details
Table 120. Geropharm Business Overview
Table 121. Geropharm Non-Insulin Therapies for Diabetes Product
Table 122. Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 123. Geropharm Recent Developments
Table 124. Alkem Labs Company Details
Table 125. Alkem Labs Business Overview
Table 126. Alkem Labs Non-Insulin Therapies for Diabetes Product
Table 127. Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 128. Alkem Labs Recent Developments
Table 129. SatRx Company Details
Table 130. SatRx Business Overview
Table 131. SatRx Non-Insulin Therapies for Diabetes Product
Table 132. SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 133. SatRx Recent Developments
Table 134. Jiangsu Hansoh Pharmaceutical Company Details
Table 135. Jiangsu Hansoh Pharmaceutical Business Overview
Table 136. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product
Table 137. Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 138. Jiangsu Hansoh Pharmaceutical Recent Developments
Table 139. Novo Nordisk Company Details
Table 140. Novo Nordisk Business Overview
Table 141. Novo Nordisk Non-Insulin Therapies for Diabetes Product
Table 142. Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 143. Novo Nordisk Recent Developments
Table 144. Emisphere Company Details
Table 145. Emisphere Business Overview
Table 146. Emisphere Non-Insulin Therapies for Diabetes Product
Table 147. Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 148. Emisphere Recent Developments
Table 149. Uni-Bio Science Group Company Details
Table 150. Uni-Bio Science Group Business Overview
Table 151. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product
Table 152. Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 153. Uni-Bio Science Group Recent Developments
Table 154. Takeda Company Details
Table 155. Takeda Business Overview
Table 156. Takeda Non-Insulin Therapies for Diabetes Product
Table 157. Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 158. Takeda Recent Developments
Table 159. 3SBio Company Details
Table 160. 3SBio Business Overview
Table 161. 3SBio Non-Insulin Therapies for Diabetes Product
Table 162. 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 163. 3SBio Recent Developments
Table 164. Jiangsu Hengrui Medicine Company Details
Table 165. Jiangsu Hengrui Medicine Business Overview
Table 166. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product
Table 167. Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2017-2022) & (US$ Million)
Table 168. Jiangsu Hengrui Medicine Recent Developments
Table 169. Research Programs/Design for This Report
Table 170. Key Data Information from Secondary Sources
Table 171. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Insulin Therapies for Diabetes Market Share by Type: 2021 VS 2028
Figure 2. Alpha-glucosidase Inhibitors Features
Figure 3. Amylin Agonists Features
Figure 4. Biguanides Features
Figure 5. Dipeptidyl Peptidase-4 (DPP4) Inhibitors Features
Figure 6. Glinides / Meglitinides Features
Figure 7. GLP-1 Analogs / GLP-1 Agonists Features
Figure 8. Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Features
Figure 9. Sulfonylureas Features
Figure 10. Thiazolidinediones Features
Figure 11. Others Features
Figure 12. Global Non-Insulin Therapies for Diabetes Market Share by Application: 2021 VS 2028
Figure 13. Monitoring Case Studies
Figure 14. Diagnosis Case Studies
Figure 15. Treatment Case Studies
Figure 16. Others Case Studies
Figure 17. Non-Insulin Therapies for Diabetes Report Years Considered
Figure 18. Global Non-Insulin Therapies for Diabetes Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 19. Global Non-Insulin Therapies for Diabetes Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 20. Global Non-Insulin Therapies for Diabetes Market Share by Region: 2021 VS 2028
Figure 21. Global Non-Insulin Therapies for Diabetes Market Share by Players in 2021
Figure 22. Global Top Non-Insulin Therapies for Diabetes Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2021)
Figure 23. The Top 10 and 5 Players Market Share by Non-Insulin Therapies for Diabetes Revenue in 2021
Figure 24. North America Non-Insulin Therapies for Diabetes Market Size YoY (2017-2028) & (US$ Million)
Figure 25. North America Non-Insulin Therapies for Diabetes Market Size Market Share by Type (2017-2028)
Figure 26. North America Non-Insulin Therapies for Diabetes Market Size Market Share by Application (2017-2028)
Figure 27. North America Non-Insulin Therapies for Diabetes Market Size Share by Country (2017-2028)
Figure 28. United States Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Canada Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Europe Non-Insulin Therapies for Diabetes Market Size YoY (2017-2028) & (US$ Million)
Figure 31. Europe Non-Insulin Therapies for Diabetes Market Size Market Share by Type (2017-2028)
Figure 32. Europe Non-Insulin Therapies for Diabetes Market Size Market Share by Application (2017-2028)
Figure 33. Europe Non-Insulin Therapies for Diabetes Market Size Share by Country (2017-2028)
Figure 34. Germany Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. France Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. U.K. Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Italy Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Russia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Nordic Countries Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size YoY (2017-2028) & (US$ Million)
Figure 41. Asia Pacific Non-Insulin Therapies for Diabetes Market Size Market Share by Type (2017-2028)
Figure 42. Asia Pacific Non-Insulin Therapies for Diabetes Market Size Market Share by Application (2017-2028)
Figure 43. Asia Pacific Non-Insulin Therapies for Diabetes Market Size Share by Region (2017-2028)
Figure 44. China Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Japan Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. South Korea Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Southeast Asia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. India Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Australia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 50. Latin America Non-Insulin Therapies for Diabetes Market Size YoY (2017-2028) & (US$ Million)
Figure 51. Latin America Non-Insulin Therapies for Diabetes Market Size Market Share by Type (2017-2028)
Figure 52. Latin America Non-Insulin Therapies for Diabetes Market Size Market Share by Application (2017-2028)
Figure 53. Latin America Non-Insulin Therapies for Diabetes Market Size Share by Country (2017-2028)
Figure 54. Mexico Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Brazil Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size YoY (2017-2028) & (US$ Million)
Figure 57. Middle East and Africa Non-Insulin Therapies for Diabetes Market Size Market Share by Type (2017-2028)
Figure 58. Middle East and Africa Non-Insulin Therapies for Diabetes Market Size Market Share by Application (2017-2028)
Figure 59. Middle East and Africa Non-Insulin Therapies for Diabetes Market Size Share by Country (2017-2028)
Figure 60. Turkey Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 61. Saudi Arabia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 62. UAE Non-Insulin Therapies for Diabetes Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 63. GSK Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 64. Eli Lilly Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 65. Sumitomo Dainippon Pharma Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 66. Intarcia Therapeutics Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 67. Servier Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 68. Pfizer Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 69. Merck Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 70. Dong-A Pharmaceutical Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 71. Luye Pharma Group Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 72. Eurofarma Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 73. Geropharm Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 74. Alkem Labs Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 75. SatRx Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 76. Jiangsu Hansoh Pharmaceutical Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 77. Novo Nordisk Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 78. Emisphere Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 79. Uni-Bio Science Group Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 80. Takeda Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 81. 3SBio Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 82. Jiangsu Hengrui Medicine Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2017-2022)
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount